Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series. Join us and your colleagues as they share their latest research, opinions on industry news, and so much more. We look forward to having you join our monthly Share-the-Science audience to experience for yourself this exciting and dynamic series!
Recorded on Wednesday, July 19th, 2017
Listen to Dr. Omar Aljitawi, MBBS, articulate the status of the field of umbilical cord blood (UCB) transplant, including advantages, current indications, and major challenges.
Overview: UCB advantages, limitations, and promising new solutions
Dr. Aljitawi is an associate professor of hematology/oncology for the University of Rochester Medical Center in Rochester, New York. In this compelling presentation, he will discuss the latest issues with UCB transplant, including the advantages and challenges as well as the limitations and the most promising approaches for overcoming those limitations. He will also explore the newly discovered role of erythropoietin in UCB stem cell function during transplant and discuss currently investigated approaches to target erythropoietin to improve umbilical cord blood transplant outcomes.
Attendees will learn about the:
- Advantages and limitations of umbilical cord blood transplant
- Major challenges in the field of umbilical cord blood transplant
- Currently investigated approaches to overcome umbilical cord blood transplant limitations
- Role of erythropoietin in umbilical cord blood transplant
Dr. Omar Aljitawi is an associate professor of hematology/oncology for the University of Rochester Medical Center in Rochester, New York. In his lab, Dr. Aljitawi focuses primarily on studying human hematopoietic stem cells and their interaction with their microenvironment. Specifically, he is studying UCB CD34+ cell interaction with erythropoietin (EPO) as a soluble factor in UCB CD34+ microenvironment.
Dr. Aljitawi has been investigating EPO signaling through EPO receptor (EPOR) effects on UCB CD34+ cell homing and engraftment. He and his research team discovered that exposure to erythropoietin impairs UCB CD34+ cell homing to the bone marrow. To translate this finding to patient care, Dr. Aljitawi and his research team investigated the use of hyperbaric oxygen (HBO) as a modality to lower systemic EPO with the aim of improving UCB CD34+ cell homing and engraftment.
Prior to his position at the University of Rochester, Dr. Aljitawi, who earned an MBBS from the University of Jordan, College of Medicine in Amman, served as an associate professor of hematology and oncology at the University of Kansas Medical Center in Kansas City, Kansas, where he completed his postdoctoral training and residency. He has published multiple journal articles and serves on the SWOG Bone Marrow and Stem Cell Transplant Committee.